Inventiva Cash And Cash Equivalents Amounted To €11.0 Million As Of March 31, 2024
Portfolio Pulse from Benzinga Newsdesk
Inventiva reported its financial results for Q1 2024, showing cash and cash equivalents of €11.0 million as of March 31, 2024. The company used €29.4 million in operating activities and €10.3 million in investing activities. Financing activities generated €23.7 million, mainly due to a €25 million loan from the European Investment Bank. Inventiva's R&D expenses increased by 82% due to clinical trials. The company has enough funds to operate until early Q3 2024 but faces material uncertainty regarding its ability to continue as a going concern.
May 21, 2024 | 8:03 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Inventiva's Q1 2024 financial results show significant cash usage in operations and investing, with a notable increase in R&D expenses. The company secured a €25 million loan from the EIB but faces material uncertainty about its ability to continue as a going concern.
The significant cash usage in operations and investing, coupled with increased R&D expenses, indicates financial strain. Although the company secured a €25 million loan, the material uncertainty about its ability to continue as a going concern is likely to negatively impact the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100